SCHEMBL3012048

SCHEMBL3012048

Cc1ccccc1Cc1csc(N2CCN(S(=O)(=O)c3ccc(CBr)cc3)CC2)n1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
TDP1 Q9NUW8 2/20 0.43
KDM4E B2RXH2 1/20 0.43
KMT2A Q03164 6/20 0.41
MEN1 O00255 4/20 0.41
LMNA P02545 3/20 0.41
MAPK1 P28482 2/20 0.41
TSHR P16473 2/20 0.41
HTT P42858 1/20 0.41
MCOLN3 Q8TDD5 1/20 0.41
USP2 O75604 2/20 0.41
MAPT P10636 1/20 0.41
RECQL P46063 1/20 0.41
HSD17B10 Q99714 1/20 0.41
HSD11B1 P28845 2/20 0.39
RAB9A P51151 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008536 0.93 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2L3MBTL1TDP1KDM4E
SCHEMBL3019696 0.90 SMN1; SMN2 (0.46) ALDH1A1SMN1; SMN2L3MBTL1TDP1KDM4E
SCHEMBL3014870 0.90 HSD11B1 (0.49) ALDH1A1SMN1; SMN2L3MBTL1TDP1KDM4E
SCHEMBL3007906 0.89 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2L3MBTL1TDP1KMT2A
SCHEMBL3016682 0.89 NPSR1 (0.48) ALDH1A1SMN1; SMN2L3MBTL1TDP1KDM4E
SCHEMBL3007289 0.89 SMN1; SMN2 (0.42) ALDH1A1SMN1; SMN2L3MBTL1KDM4EKMT2A
SCHEMBL3017462 0.88 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2L3MBTL1TDP1KDM4E
SCHEMBL3005487 0.88 USP2 (0.47) ALDH1A1SMN1; SMN2L3MBTL1KDM4EKMT2A
SCHEMBL3014736 0.87 SMN1; SMN2 (0.47) ALDH1A1SMN1; SMN2L3MBTL1TDP1KDM4E
SCHEMBL3010800 0.86 HSD11B1 (0.56) ALDH1A1SMN1; SMN2L3MBTL1TDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885SMN1; SMN2 1/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.